These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35075214)

  • 1. Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.
    Geng JH; Plym A; Penney KL; Pomerantz M; Mucci LA; Kibel AS
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):320-326. PubMed ID: 35075214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin use and outcomes of oncological treatment for castration-resistant prostate cancer.
    Peltomaa AI; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Sci Rep; 2023 Nov; 13(1):18866. PubMed ID: 37914793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
    Jung J; Lee C; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Korean J Urol; 2015 Sep; 56(9):630-6. PubMed ID: 26366275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
    Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
    Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
    Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
    Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
    Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
    Sharma J; Gray KP; Harshman LC; Evan C; Nakabayashi M; Fichorova R; Rider J; Mucci L; Kantoff PW; Sweeney CJ
    Prostate; 2014 Jun; 74(8):820-8. PubMed ID: 24668612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
    Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
    Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
    Ji G; Song G; Huang C; He S; Zhou L
    Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
    Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
    Nishizawa K; Hattahara K; Onishi H; Yoshida T
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
    Huang FM; Li XH; Liang Y
    Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
    Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.